Additional Information

Description

Flublok® 2025–2026 (Flu-112) is a recombinant quadrivalent influenza vaccine designed to provide protection against influenza A and B viruses expected during the 2025–2026 flu season. This vaccine is produced using recombinant DNA technology, which does not require the use of eggs, offering an alternative for individuals with egg allergies. The formulation contains hemagglutinin proteins from two influenza A strains and two influenza B strains as recommended by the World Health Organization (WHO).

The product is supplied in 0.5 mL prefilled syringes, with each box containing 10 single-dose units. The vaccine is indicated for individuals aged 18 years and older. Each 0.5 mL dose is administered via intramuscular injection, typically in the deltoid muscle for adults. Flublok® is preservative-free and is provided as a ready-to-use solution, which eliminates the need for reconstitution or dosage measurement.

Common side effects may include pain at the injection site, redness, swelling, fever, headache, and muscle aches. Serious adverse events, although rare, may include allergic reactions or anaphylaxis. The vaccine is contraindicated in individuals with a known hypersensitivity to any component of the vaccine.